New COVID-19 Variant BA.3.2 'Cicada' Emerges as Global Concern
A new and concerning variant of COVID-19, designated BA.3.2 and colloquially named 'Cicada', is currently spreading across the United States and numerous other countries worldwide. This heavily mutated strain poses a significant challenge as it demonstrates an ability to evade immunity conferred by existing vaccines and prior infections. Although it first emerged over a year ago, cases of the BA.3.2 variant have seen a gradual but steady increase globally, raising alarms among public health officials and virologists.
Rapid Spread Across the United States
According to the latest data from the Centers for Disease Control and Prevention (CDC), as of early April 2026, the BA.3.2 variant has been detected in more than half of all American states. The variant's nickname, 'Cicada', was coined by T. Ryan Gregory, Ph.D., a professor of evolutionary biology at the University of Guelph, who is also known for naming other strains such as 'stratus' and 'pirola'. This naming reflects the variant's persistent and emerging nature, much like the insect it is named after.
Genetic Mutations and Immune Evasion
What particularly worries experts is the extensive genetic alterations found in the spike protein of the BA.3.2 variant. Andrew Pekosz, PhD, a virologist at the Johns Hopkins Bloomberg School of Public Health, explained to TODAY.com that these mutations are substantial. "It has a lot of mutations that may cause it to look different to your immune system," Pekosz stated. This distinct genetic profile sets BA.3.2 apart from other circulating variants and could potentially diminish the protective effects of previous vaccinations or infections.
A study published in the CDC's Morbidity and Mortality Weekly Report supports these concerns, indicating that the variant's mutations have the capacity to reduce immunity levels in populations. The spike protein changes are critical as they are the primary target for most COVID-19 vaccines, suggesting that current formulations might be less effective against this new strain.
Origin and Evolution of BA.3.2
The BA.3.2 variant was first identified in November 2024 in South Africa. It is a direct descendant of BA.3, an Omicron subvariant that appeared in 2022 and briefly co-circulated with other Omicron strains like BA.1 and BA.2. While BA.3 initially faded from prominence, it never completely disappeared. Over the subsequent two years, it accumulated further mutations, eventually giving rise to BA.3.2. For much of its early existence, this strain was overshadowed by more widespread and dangerous variants such as nimbus and XFG. It was not until September 2025 that cases of BA.3.2 began to surge significantly, marking its arrival as a variant of concern.
Severity and Global Distribution
Despite its ability to evade immunity, there is currently no evidence to suggest that BA.3.2 causes more severe illness or leads to higher hospitalization rates. Dr. Adolfo Garcia-Sastre, director of the Global Health and Emerging Pathogens Institute at Mount Sinai, emphasized this point, noting that in countries where the variant is widespread, it has not been linked to increased disease severity. "While it can cause problems, it's not a 'more problematic' strain than previous ones," he told the outlet.
Globally, the BA.3.2 variant has spread to 33 countries, with the highest concentrations of cases reported in Australia, Denmark, Germany, and the Netherlands. In the United States, it is currently active in 31 states, including:
- California
- New York
- Texas
- Florida
- Illinois
- Pennsylvania
- Ohio
- Michigan
- Georgia
- North Carolina
- New Jersey
- Virginia
- Washington
- Massachusetts
- Indiana
- Tennessee
- Missouri
- Maryland
- Wisconsin
- Minnesota
- Colorado
- Alabama
- South Carolina
- Louisiana
- Kentucky
- Oregon
- Oklahoma
- Connecticut
- Utah
- Iowa
- Nevada
Symptoms and Diagnostic Challenges
The symptoms associated with the BA.3.2 variant are largely consistent with those caused by other COVID-19 strains. According to the CDC, common symptoms include:
- Cough
- Fever or chills
- Sore throat
- Congestion
- Shortness of breath
- Loss of smell or taste
- Fatigue
- Headache
- Diarrhea or vomiting
It is crucial to note that these symptoms overlap significantly with those of influenza and respiratory syncytial virus (RSV), both of which continue to circulate. Therefore, testing remains essential for accurate diagnosis and appropriate treatment, preventing misidentification and ensuring timely medical intervention.
Vaccination and Public Health Recommendations
The unique spike protein mutations in BA.3.2 have prompted discussions about the potential need for vaccine reformulation. Experts indicate that these genetic changes may impact the efficacy of current vaccines. "It's not completely clear how effective the current vaccine will be, but it likely still has some effectiveness," said Dr. Garcia-Sastre. In the interim, public health authorities advise several precautionary measures:
- Monitor for symptoms closely and isolate if you become ill.
- Wear masks in high-risk settings such as crowded indoor spaces.
- Consult with healthcare providers about booster shots, especially if you have not been vaccinated or infected with COVID-19 in the last 6-12 months.
Vaccination continues to be critically important for individuals at higher risk of severe disease, including adults over the age of 65 and those with weakened immune systems or underlying health conditions. "Vaccination is still going to help limit cases," Pekosz affirmed, underscoring that while protection may be reduced, it is not entirely absent.
As the BA.3.2 variant continues to spread, ongoing surveillance, research, and public awareness are key to managing its impact. Health officials stress the importance of staying informed through reliable sources and adhering to recommended guidelines to mitigate transmission and protect vulnerable populations.
